Next™ BriefSmart Contact Lenses and Wearable Displays on the Eye
Buy Now
Meticulous Next™HealthcareNov 2026104 ppMRN-1682

Smart contact lenses Market Outlook 2026–2036: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

Brief ID: MRN-1682Format: PDF + Summary DeckDelivery: InstantHorizon: 10-yr horizonSignal: Emerging
Buy Now · $1,250
Adoption maturity (indexed)
Mainstream inflection: ~2031
Horizon: 2026–2036 · Signal: Emerging
10 yrs
Forward horizon
~2031
Mainstream inflection
Emerging
Signal strength

What This Brief Covers

This Meticulous Next™ brief examines smart contact lenses, lenses that carry sensors, drug reservoirs or displays and read or act on the eye and its fluids. It tests whether lenses move from one approved monitoring device and many prototypes to a regulated product category in eye care and a wearable platform by 2036, and what that means for eye care companies, medical device makers, technology groups and patients.

One monitoring lens is already on the market. The Sensimed Triggerfish is an FDA-approved lens for 24-hour monitoring of changes linked to intraocular pressure in glaucoma. The device reports ocular dimensional changes and not conventional pressure in millimetres of mercury. The conclusion is that regulators have accepted a smart lens for clinical use, although the output is a pattern and not a direct pressure reading, and this limits how far the product can replace standard tests.

Research is moving toward lenses that act as well as sense. On 8 April 2026 the Terasaki Institute in California reported in Science Translational Medicine a lens that tracks intraocular pressure with no electronics or battery and releases drug in pulses when pressure rises, tested in live rabbits and in cow eyes. The developers plan a small human trial, and the monitoring part could reach approval faster than the drug-delivery part. The conclusion is that closed-loop treatment lenses are preclinical, and monitoring comes to patients first.

Display lenses attract the largest funding. XPANCEO, a company in the United Arab Emirates, raised USD 250 million in July 2025 at a valuation of USD 1.35 billion, led by Opportunity Venture (Asia), and showed five working prototypes at MWC 2026 and again at VivaTech in June 2026. It aims to finish a full prototype by the end of 2026 and has told the press that a version could reach shelves as soon as 2030. The conclusion is that eye-worn displays remain a development programme, and the first consumer products depend on safety testing that has not yet been published.

The brief treats smart contact lenses as an emerging signal with a ten year horizon to 2036. It identifies which eye care companies, device makers and technology groups capture value as lenses move from prototypes to regulated products. It is a focused 104-page decision brief that presents an indicative trajectory rather than a segmented market model.

Brief Snapshot
ParameterDetails
Forward horizon2026–2036 (10 years)
Emerging forceSmart contact lenses
Technology readinessOne FDA-approved monitoring lens on the market; glucose, drug-delivery and display lenses at prototype and preclinical stage
Indicative market size & forecastThe smart contact lenses market, covering electronic and sensing contact lenses for intraocular pressure monitoring, glucose sensing, drug delivery and eye-worn displays, including regulated monitoring lenses and clinical and development programme revenue, and excluding non-electronic vision-correction and myopia-control lenses and smart glasses, is valued at USD 0.02–0.05 billion in 2026 and is projected to reach USD 1.15–2.88 billion by 2036, at a CAGR of 50%
Mainstream inflection~2031, when a lens for glucose or pressure monitoring with a clinical claim and a display lens for consumers are both available through regulated channels
Signal strengthAn approved monitoring lens, a USD 250 million round for a display lens developer and a published drug-releasing lens in animals
Primary beneficiariesEye care and contact lens companies; medical device makers; technology groups; patients with glaucoma and diabetes
Brief length / format104 pages · PDF + executive summary deck · instant delivery

Understanding the Technology

Sensing lenses measure the eye and its fluids. Pressure lenses track changes in the shape of the cornea, and glucose lenses read tear glucose with an electrode. Published studies often have small samples and wear times under 72 hours, and tear glucose is harder to relate to blood glucose than to the fluid in tissue. The conclusion is that clinical proof of accuracy is the main step between a prototype and a medical claim.

Drug-delivery lenses release a medicine at the right time. The Terasaki lens uses a soft chamber that changes volume when pressure changes the cornea and releases drug without a battery, and other lenses release drugs on chemical triggers. The conclusion is that treatment lenses face the stricter drug-device approval route, which takes longer than monitoring.

Display lenses place pixels on the eye. XPANCEO describes a micro display built into the lens, with wireless power from a case, and notes that radiation is comparable to Bluetooth headphones, which outside testing has not yet confirmed. Another company in the field has a micro LED display about 0.48 mm across. The conclusion is that power, heat and safety, not the display itself, set the timeline for consumer lenses.

Power and data are the engineering limits. A lens has no room for a battery of useful size, so power comes from wireless charging or from designs without electronics, and data pass to a phone. The conclusion is that designs without batteries suit medical monitoring first, and displays depend on wireless power developments.

The limits are clinical proof of accuracy, safe wear time and comfort, regulatory approval, cost and the lack of insurance coverage for new devices. The brief tests each limit against the evidence to 2036.

Market Outlook

The smart contact lenses market, covering electronic and sensing contact lenses for intraocular pressure monitoring, glucose sensing, drug delivery and eye-worn displays, including regulated monitoring lenses and clinical and development programme revenue, and excluding non-electronic vision-correction and myopia-control lenses and smart glasses, is valued at USD 0.02–0.05 billion in 2026 and is projected to reach USD 1.15–2.88 billion by 2036, at a CAGR of 50%.

The 2026 base rests on sales of the one regulated monitoring lens, clinical and development programme revenue, and early sales to research users. Growth then follows regulatory approvals, the number of lens wearers with a clinical indication, the price per lens and the launch of display lenses.

The forecast is sensitive to the results of the first human trials, the speed of approval for monitoring and treatment lenses and the safety record of display lenses.

Scenarios

Scenarios.

The base case assumes that a pressure or glucose lens enters pivotal trials by 2029, that a second regulated monitoring lens is approved by 2031 and that a display lens reaches limited consumer sale by 2032, bringing the inflection to about 2031 and a 2036 value near the middle of the range. An accelerated case assumes that human trials confirm accuracy early and that display lenses launch by 2030, moving the inflection to 2029 and lifting the 2036 value to the top of the range. A delayed case assumes that trials show poor accuracy and that safety questions delay displays, moving the inflection to 2034 and holding growth at the bottom of the range.

Factors Behind Growth

Growth drivers

  • Large unmet need for continuous monitoring in glaucoma and diabetes.
  • Venture funding for display lens developers.
  • Published prototypes of lenses that sense and release drugs.
  • One FDA-approved monitoring lens as a regulatory precedent.

Enablers

  • Soft flexible electronics and polymers.
  • Micro displays and wireless power.
  • Tear fluid and pressure sensors.
  • Phone connectivity and artificial intelligence for readings.

Restraints and barriers

  • Lack of human data on accuracy.
  • Limits on wear time, comfort and safety.
  • Longer approval route for drug-delivery lenses.
  • Cost and lack of insurance coverage.

The Forces at Play

The direction of smart contact lenses is set by clinical evidence, regulatory approval, the safety of power and display designs and the willingness of eye care companies and technology groups to invest.

The brief assesses standards and policy, company and investor funding, technology readiness, product and manufacturing readiness and customer readiness, and rates each force for direction, speed and confidence.

Adoption Outlook

How the shift is likely to unfold across three time horizons.

Near term2026–2029
Human trials

Monitoring lenses enter human trials, display prototypes are finished and the first partnerships with eye care companies are signed.

Mid term2029–2032
First regulated products

A second monitoring lens is approved, and the first display lenses reach consumers in limited markets.

Long term2032–2036
Platform

Lenses combine monitoring, treatment and display with phone and clinical systems.

Latest Strategic Developments

DateDevelopmentTypeSignificance
Jul 2025XPANCEO raises USD 250 million at a USD 1.35 billion valuation, led by Opportunity Venture (Asia)FundingFunds display lens development
Mar 2026XPANCEO shows five working smart lens prototypes at MWC 2026ProductShows display and sensing prototypes
Apr 2026The Terasaki Institute reports a drug-releasing pressure-sensing lens in Science Translational MedicineResearchShows a lens that senses and treats in animals
Jun 2026XPANCEO shows its prototypes again at VivaTech and targets a full prototype by the end of 2026ProductSets a prototype date
2026Researchers report a lens with a resistive pressure sensor for real-time monitoring in npj Flexible ElectronicsResearchAdds a new sensing design
Late 2026XPANCEO plans to complete its first full prototype and show it in early 2027ProgrammeMarks the first full display lens

Key Players & Competitive Landscape

The key participants in smart contact lenses include Alcon Inc., Johnson & Johnson, The Cooper Companies, Inc., Bausch + Lomb Corporation, Menicon Co., Ltd., EssilorLuxottica SA, Hoya Corporation, Glaukos Corporation, Santen Pharmaceutical Co., Ltd., Ocular Therapeutix, Inc., Carl Zeiss Meditec AG, Abbott Laboratories, Dexcom, Inc., Medtronic plc, Samsung Electronics Co., Ltd., Sony Group Corporation, Apple Inc., Meta Platforms, Inc., Konica Minolta, Inc., Alphabet Inc., Sensimed, XPANCEO, Mojo Vision, the Terasaki Institute for Biomedical Innovation and Intra-Ker.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as lenses move from prototypes to regulated products.

Alcon Inc., Johnson & Johnson and The Cooper Companies, Inc. lead among contact lens companies, Sensimed leads among regulated monitoring lenses and XPANCEO leads among display lens developers by funding. Competitive intensity is low and rising as large eye care groups and technology groups enter.

ArchetypeRepresentative playersPositionOutlook
Contact lens and eye care companiesAlcon Inc., Johnson & Johnson, The Cooper Companies, Inc., Bausch + Lomb Corporation, Menicon Co., Ltd., EssilorLuxottica SA, Hoya CorporationContact lenses and eye careOffer distribution, manufacturing and clinical access
Glaucoma and ocular drug companiesGlaukos Corporation, Santen Pharmaceutical Co., Ltd., Ocular Therapeutix, Inc., Carl Zeiss Meditec AGEye disease treatment and diagnosticsProvide drugs and clinical partnerships
Diabetes monitoring companiesAbbott Laboratories, Dexcom, Inc., Medtronic plcGlucose monitoringOffer glucose sensing expertise and reimbursement experience
Technology groupsSamsung Electronics Co., Ltd., Sony Group Corporation, Apple Inc., Meta Platforms, Inc., Alphabet Inc., Konica Minolta, Inc.Displays, sensors and wearablesSupply displays, sensors and wearable platforms
Lens developersSensimed, XPANCEO, Mojo VisionSmart lensesDevelop monitoring and display lenses
Research bodiesTerasaki Institute for Biomedical Innovation, Intra-KerResearch and devicesDevelop new sensing and drug-delivery designs

Where value migrates.

In 2026 value sits with developers that hold the approved monitoring lens and the funded display prototypes. By 2031 it moves toward eye care companies that supply manufacturing and clinical access, and toward diabetes and glaucoma companies that hold reimbursement and care pathways. By 2036 it settles with companies that combine lens manufacturing, sensing and data services, and with technology groups that run display platforms. Margins hold for regulated monitoring products and narrow for lenses sold on display features alone.

Who Will Win — and Why

The archetypes best positioned to capture value as the shift matures.

Contact lens companies with manufacturing scale

Lens makers have the production and clinical channels that start-ups lack.

Monitoring lens developers with regulatory approval

An approved lens shows the path to clinical use and reimbursement.

Technology groups with display and wireless power know-how

Displays and power are the main limits for consumer lenses.

Regulatory Landscape

JurisdictionMilestoneIndicative timingEffect on adoption
FDA device approvalTriggerfish is FDA approved for 24-hour pressure-related monitoring in glaucomaApprovedSets the precedent for monitoring lenses
Drug-device combination rulesLenses that release drugs face stricter standards than monitoring lensesOngoingLengthens the path for treatment lenses
Consumer product safetyDisplay lenses must show eye safety for continuous wear, including heat and radiationEmergingSets the timeline for display lenses
Clinical evidence standardsTrials larger than current small studies with wear times under 72 hours are neededOngoingDefines the evidence required
ReimbursementPayers decide coverage for monitoring lensesEmergingDecides the size of clinical sales

Investment Signals

Unmet clinical need, venture funding, published prototypes and an approved precedent support growth, while the lack of human data, wear and safety limits, the longer route for drug-delivery lenses and cost hold back the pace.

A trial result, a regulatory decision or a safety finding could shift the pace. The brief therefore tracks four indicators: human trials started, regulatory approvals, funding and partnerships with eye care companies, and wear time achieved.

Human trials, then a second regulated monitoring lens, then display lenses and combined platforms is the expected order of change.

Questions This Brief Answers

01What are smart contact lenses, and how do they differ from smart glasses and standard lenses?
02What is the market size in 2026, and what is the forecast to 2036?
03Which lens types and technologies are advancing?
04What factors are driving growth, and what barriers remain?
05Which key participants are active, and which archetypes are positioned to win?
06What are the latest developments?
07How will clinical evidence and regulation shape the market between 2026 and 2036?
08What should eye care companies, device makers, technology groups and investors do now?

Strategic Implications

  • Eye care companies: partner with lens developers for manufacturing and clinical access, starting with monitoring.
  • Glaucoma and diabetes companies: test lenses against standard monitoring and plan reimbursement.
  • Lens developers: publish human accuracy and safety data and prepare for regulatory filings.
  • Technology groups: develop wireless power and displays that meet eye safety needs.
  • Investors: favour developers with regulatory progress and clinical partners over those with display prototypes only.
Analyst Perspective

"The first lenses that matter will measure the eye. The ones that follow will put the screen in it."

Lead Foresight Analyst
Healthcare & Life Sciences · Meticulous Next™

Table of Contents

Access & Licensing

A focused foresight brief, priced to circulate. Every option is delivered instantly and backed by analyst support.

Single Brief
$1,250
One named user
Full PDF brief
Executive summary deck
One named user
Free outlook update
★ Most Popular
Team License
$1,750
Up to 10 users
Access for 2–10 users
Internal sharing rights
30-minute analyst briefing
Enterprise
$2,050
Organization-wide
Organization-wide access
Unlimited users
Priority analyst access
Custom extracts
Included with
every brief
Analyst-reviewed foresightMulti-signal validationInstant deliveryFree outlook updates

Frequently Asked Questions

Search Market Intelligence

Search across reports, blogs, press releases, and industries